Clinical Trial: A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07594587) titled 'A Study of Ruxolitinib in Patients With Graft-Versus Host Disease' on May 11.

Brief Summary: This study aims to evaluate the safety and effectiveness of Jakavi(R) (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.

Study Start Date: May 31

Study Type: OBSERVATIONAL

Condition: Graft-Versus-Host Disease

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Pharmaceuticals

Published by HT Digital Content Services with permission from Health Daily Digest....